A novel gene expression signature in peripheral blood mononuclear cells for early detection of colorectal cancer

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 5, 2014, Pages 507-517

  Nichita, C ^a   Ciarloni, L ^b,c   Monnier Benoit, S ^b   Hosseinian, S ^b   Dorta, G ^a   Ruegg C ^c,d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Diagnoplex SA   (Switzerland)

^c EPFL   (Switzerland)

^d University of Fribourg   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOMATOUS POLYPS; ADULT; AGED; AGED, 80 AND OVER; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84893803041     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12618     Document Type: Article

References (48)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Wilson JMG, Jungner G,. Principles and Practice of Screening for Disease. Geneva: WHO, 1968.
3. Levin B, Liberman DA, McFarland B, et al,. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline for the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenerology 2008; 134: 1570-95.
4. Parente F, Boemo C, Ardizzoia A, et al,. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy. Endoscopy 2013; 45: 27-34.
5. Jean-Jacques M, Kaleba EO, Gatta JL, Gracia G, Ryan ER, Choucair BN,. Program to improve colorectal cancer screening in a low-income, racially diverse population: a randomized controlled trial. Ann Fam Med 2012; 10: 412-7.
6. Von Wagner C, Baio G, Raine R, et al,. Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England. Int J Epidemiol 2011; 40: 712-8.
7. Grützmann R, Molnar B, Pilarsky C, et al,. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS ONE 2008; 3: e3759.
8. Han M, Liew CT, Zhang HW, et al,. Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin Cancer Res 2008; 14: 455-60.
9. Marshall KW, Mohr S, Khettabi F, et al,. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer 2010; 126: 1177-86.
10. Church TR, Wandell M, Lofton-Day C, et al,. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014; 3: 317-25.
11. Lorusso G, Rüegg C,. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 2008; 130: 1091-103.
12. Coussens LM, Werb Z,. Inflammation and cancer. Nature 2002; 420: 860-7.
13. Laurent J, Hull EF, Touvrey C, et al,. Proangiogenic factor PIGF programs CD11b(+) myelomonocytes in breats cancer during differentiation of their hematopoietic progenitors. Cancer Res 2011; 71: 3781-91.
14. Cofflet SB, Tal AO, Scholz A, et al,. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 2010; 70: 5270-80.
15. Sharma P, Sahni NS, Tibshirani R, et al,. Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res 2005; 7: R634-44.
16. Twine NC, Stover JA, Marshall B, et al,. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res 2003; 63: 6069-75.
17. Burczynski ME, Twine NC, Dukart G, et al,. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal carcinoma. Clin Cancer Res 2005; 11: 1181-9.
18. Showe MK, Vachani A, Kossenkov AV, et al,. Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res 2009; 69: 9202-10.
19. Osman I, Bajorin DF, Sun TT, et al,. Novel blood biomarkers of human urinary bladder cancer. Clin Cancer Res 2006; 12 (11 Pt 1): 3374-80.
20. Honda M, Sakai Y, Yamashita T, et al,. Differential gene expression profiling in blood from patients with digestive system cancers. Biochemic Biophys Res Commun 2010; 400: 7-15.
21. 't Hoen PA, Ariyurek Y, Thygesen HH, et al,. Deep sequencing-based expression analysis shows major advances in robustness, resolution and inter-lab portability over five microarray platforms. Nucleic Acids Res 2008; 36: e141.
22. Robinson MD, Smyth GK,. Small-sample estimation of negative binomial dispersion, with applications to SAGE data. Biostatistics 2008; 9: 321-32.
23. Robinson MD, Smyth GK,. Moderated statistical tests for assessing differences in tag abundance. Bioinformatics 2007; 23: 2881-7.
24. White JR, Nagarajan N, Pop M,. Statistical methods for detecting differentially abundant features in clinical metagenomic samples. PLoS Comput Biol 2009; 5: e1000352.
25. Therianos S, Zhu M, Pyun E, Coleman PD,. Single-channel quantitative multiplex reverse transcriptase-polymerase chain reaction for large numbers of gene products differentiates nondemented from neuropathological Alzheimer's disease. Am J Pathol 2004; 164: 795-806.
26. Wilcoxon Frank,. Individual comparisons by ranking methods. Biometrics Bulletin. 1945; 1: 80-3.
27. Dobson AJ,. An Introduction to Generalized Linear Models. 2nd ed. Boca Raton: Chapman & Hall/CRC, 2002.
28. McCullagh P, Nelder JA,. Generalized Linear Models. 2nd ed. Boca Raton: Chapman & Hall/CRC, 1989.
29. Breiman L, Friedman JH, Olshen RA, Stone CJ,. Classification and Regression Trees (CART). Belmont: Wadsworth, 1984.
30. Geman D, d'Avignon C, Naiman DQ, Winslow RL,. Classifying gene expression profiles from pairwise mRNA comparisons. Stat Appl Genet Mol Biol. 2004; 3: Article 19.
31. Park MY, Hastie T,. L1 regularization path algorithm for generalized linear models. J R Stat Soc B 2007; 69: 659-77.
32. Friedman J, Hastie T, Tibshirani R,. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw 2010; 33: 1-22.
33. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD,. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001; 54: 774-81.
34. Morrissy AS, Morin RD, Delaney A, et al,. Next-generation tag sequencing for cancer gene expression profiling. Genome Res 2009; 19: 1825-35.
35. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y,. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129: 422-8.
36. de Wijkerslooth TR, Stoop EM, Bossuyt PM, et al,. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol 2012; 107: 1570-8.
37. Young TL, Matsuda T, Cepko CL,. The noncoding RNA taurine upregulated gene 1 is required for differentiation of the murine retina. Curr Biol 2005; 15: 501-12.
38. Han Y, Liu Y, Gui Y, Cai Z,. Long intergenic non-coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder. J Surg Oncol 2013; 107: 555-9.
39. Chambon M, Orsetti B, Berthe ML, et al,. Prognostic significance of TRIM24/TIF-1α gene expression in breast cancer. Am J Pathol 2011; 178: 1461-9.
40. Cui Z, Cao W, Li J, Song X, Mao L, Chen W,. TRIM24 overexpression is common in locally advanced head and neck squamous cell carcinoma and correlates with aggressive malignant phenotypes. PLoS ONE 2013; 8: e63887.
41. Li H, Sun L, Tang Z, et al,. Overexpression of TRIM24 correlates with tumor progression in non-small cell lung cancer. PLoS ONE 2012; 7: e37657.
42. Gandini D, De Angeli C, Aguiari G, et al,. Preferential expression of the transcription coactivator HTIF1alpha gene in acute myeloid leukemia and MDS-related AML. Leukemia 2002; 16: 886-93.
43. Herszényi L, Sipos F, Galamb O, et al,. Matrix metalloproteinase-9 expression in normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon. Pathol Oncol Res 2008; 14: 31-7.
44. Kang JC, Chen JS, Lee CH, Chang JJ, Shieh YS,. Intratumoral macrophage counts correlate with tumor progression in colorectal cancer. J Surg Oncol 2010; 102: 242-8.
45. Zaman K, Driscoll R, Werffeli P, et al,. Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy nt. J Cancer 2006; 118: 755-64.
46. Lakatos G, Sipos F, Miheller P, et al,. The behavior of matrix metalloproteinase-9 in lymphocytic colitis, in collagenous colitis and ulcerative colitis. Pathol Oncol Res 2012; 18: 85-91.
47. Bleeker SE, Moll HA, Steyerberg EW, et al,. External validation is necessary in prediction research: a clinical example. J Clin Epidemiol 2003; 56: 826-32.
48. Gebhardt C, Németh J, Angel P, Hess J,. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006; 72: 1622-31.